As of May 29, 2025, Guided Therapeutics Inc (GTHP) reports a ROE (Return on Equity) of -384.96%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Guided Therapeutics Inc's ROE (Return on Equity)
Over recent years, Guided Therapeutics Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | -384.96% |
| 2023-12-31 | 91.67% |
| 2022-12-31 | 150.69% |
| 2021-12-31 | 37.98% |
| 2020-12-31 | 2.58% |
This slight downward trend highlights how Guided Therapeutics Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Guided Therapeutics Inc's ROE (Return on Equity) to Peers
To better understand Guided Therapeutics Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Guided Therapeutics Inc (GTHP) | -384.96% |
| Echo Therapeutics Inc (ECTE) | 878.82% |
| Biolife Sciences Inc (BLFE) | 747.83% |
| Bionoid Pharma Inc (BINP) | 541.05% |
| ArtVentive Medical Group Inc (AVTD) | 365.48% |
| Medizone International Inc (MZEIQ) | 44.29% |
Compared to its competitors, Guided Therapeutics Inc's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.